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Abstract The mevalonate-independent 2-C-methyl-D-erythritol
4-phosphate (MEP) pathway for isoprenoid biosynthesis is
essential in many eubacteria, plants, and the malaria parasite.
Using genetically engineered Escherichia coli cells able to utilize
exogenously provided mevalonate for isoprenoid biosynthesis by
the mevalonate pathway we demonstrate that the lytB gene is
involved in the trunk line of the MEP pathway. Cells deleted for
the essential lytB gene were viable only if the medium was
supplemented with mevalonate or the cells were complemented
with an episomal copy of lytB. ß 2001 Federation of European
Biochemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Isoprenoids play essential roles in all organisms, as in elec-
tron transfer, photosynthesis, membrane stability, and cell
signalling. In animals, fungi, archaebacteria, and certain bac-
teria the biosynthesis of isopentenyl pyrophosphate (IPP) and
its isomer dimethylallyl pyrophosphate (DMAPP), the precur-
sors of all isoprenoids, proceeds exclusively by the mevalonate
(MVA) pathway. However, in many eubacteria, including Es-
cherichia coli, algae, plastids of plants, and in the apicomplex-
an protozoa Plasmodium falciparum, the alternative MVA-in-
dependent 2-C-methyl-D-erythritol 4-phosphate (MEP)
pathway is operative for isoprenoid biosynthesis [1^4].
Although the ¢rst ¢ve enzymatic steps of the MEP pathway
have been described, the terminal steps are still unknown. The
pathway initiates with the formation of 1-deoxy-D-xylulose 5-
phosphate (DOXP) by condensation of pyruvate and D-glyc-
eraldehyde 3-phosphate catalyzed by the DOXP synthase
(Dxs). DOXP is then converted into MEP by the DOXP
reductoisomerase (Dxr) (Fig. 1). The enzymes encoded by
the genes ygbP (ispD), ychB (ispE) and ygbB (ispF) mediate
the formation of 2-C-methyl-D-erythritol 2,4-cyclodiphos-
phate, with 4-diphosphocytidyl-2-C-methyl-D-erythritol and
4-diphosphocytidyl-2-C-methyl-D-erythritol 2-phosphate as in-
termediates [1^4].
By constructing deletion mutants of E. coli it was demon-
strated that all known enzymes are involved in the trunk line
of the MEP pathway in vivo [5,6] and that the pathway
branches to synthesize IPP and DMAPP [7] (Fig. 1). These
experiments were carried out with E. coli cells genetically en-
gineered to be able to utilize exogenously provided MVA for
isoprenoid biosynthesis by the classical MVA pathway. Using
these cells it is possible to identify novel enzymes involved in
the trunk line of this pathway as recently shown for GcpE
[8,9].
Recently, evidence was given that an enzyme encoded by
the lytB gene in the cyanobacterium Synechocystis catalyzes
an essential step at, or subsequent to, the point at which the
MEP pathway branches to form IPP and DMAPP [10]. LytB
was originally described in E. coli as a gene involved in me-
diating penicillin tolerance [11], and subsequently identi¢ed in
various other Gram-negative bacteria [12]. Using a genetic
approach we now demonstrate that LytB is essentially in-
volved in the trunk line of the MEP pathway in E. coli.
2. Materials and methods
2.1. Strains and media
All plasmids were constructed in E. coli TOP10 (Invitrogen). For
gene replacement experiments, the recombination pro¢cient wild-type
K-12 strain E. coli DSM No. 498 (ATCC 23716) was used. Bacteria
were grown in Standard 1 medium (Merck) at 37‡C with aeration. For
solid medium, agar (Difco Bacto agar) was added to 1.5% (w/v).
Media were supplemented with 150 Wg/ml ampicillin, 25 Wg/ml chlor-
amphenicol or 100 WM MVA, where appropriate. MVA was prepared
as described [7]. For selection against sacB, salt-free LB medium [13]
was supplemented with sucrose to a ¢nal concentration of 6% (w/v).
2.2. Recombinant DNA techniques
Plasmid isolation, agarose gel electrophoresis, ligation and trans-
formation of plasmid DNA were carried out according to standard
protocols [14]. For analytical plasmid preparation, the GFX1 Micro
Plasmid Prep kit (Amersham Pharmacia) was used. DNA fragments
were gel puri¢ed using the Easy Pure kit (Biozym Diagnostik). Re-
striction endonuclease digestions were carried out according to the
speci¢ed recommendations of the manufacturer (Promega).
2.3. PCR
All PCRs were performed in a total volume of 20 Wl using a Stra-
tagene robocycler with a heated lid and the expand high ¢delity PCR
system (Roche Diagnostics). An initial denaturation at 94‡C for 1 min
was followed by 30 cycles of denaturation at 94‡C for 30 s, annealing
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at 50‡C for 30 s and extension at 72‡C for 30 s to 90 s, dependent on
the expected size of the products. A ¢nal 7-min 72‡C step was added
to allow complete extension of the products.
2.4. Construction of the gene replacement plasmids pKO3-vlytB
For generation of precise in-frame deletion mutants of E. coli, the
pKO3 vector was used [15]. Crossover PCR deletion products were
constructed basically as described previously [15]. First, two di¡erent
asymmetric PCRs were used with the primer pair LytB-N-out and
LytB-N-in to generate a fragment upstream (559 bp) and with the
primer pair LytB-C-in and LytB-C-out to generate a fragment down-
stream (537 bp) of the sequence targeted for deletion (Table 1). The
primer pairs were in a 10:1 molar ratio (500 nM outer primer and 50
nM inner primer). Then, both fragments were annealed at their over-
lapping region and ampli¢ed to a single fragment, using 500 nM of
the outer primers, LytB-N-out and LytB-C-out. The resulting frag-
ment was cloned using the pCR-TOPO-TA cloning kit (Invitrogen)
and veri¢ed by restriction analysis and sequencing. The fragment was
released from the pCR-TA vector by BamHI and SalI digestion, gel-
puri¢ed, ligated into the BamHI- and SalI-digested pKO3 vector, and
transformed into wild-type E. coli. Colonies growing on chloramphe-
nicol plates at 30‡C were screened for inserts by analytical plasmid
preparation and restriction analysis.
2.5. Construction of the mutant strain wtvlytB
Gene replacement experiments were carried out as described previ-
ously except for supplementing the plates with 100 WM MVA [15].
The gene replacement plasmid pKO3-vlytB was transformed into
wild-type E. coli cells harboring the pSC-MVA plasmid [8] and al-
lowed to recover for 1 h at 30‡C. Bacteria with the plasmid integrated
into the chromosome were selected by a temperature shift to 43‡C. By
screening for sucrose resistance and chloramphenicol sensitivity, bac-
teria with lost vector sequences were selected and tested for the de-
sired genotype by PCR. The lytB deletion was con¢rmed using the
primer pair LytB-con-N and LytB-con-C. Bacteria with the desired
deletion as veri¢ed by PCR were tested for growth with and without
MVA.
2.6. Complementation experiment
The mutant strain wtvlytB was complemented by transformation
Fig. 1. The MEP pathway of IPP and DMAPP biosynthesis in E.
coli, and genetically engineered synthesis of IPP from exogenously
supplied MVA. Interrupted lines indicate not fully elucidated steps.
Mvk, MVA kinase; Pmk, phosphomevalonate kinase; Mpd, MVA
pyrophosphate decarboxylase; Dxs, DOXP synthase; Dxr, DOXP
reductoisomerase; Ipi, IPP isomerase.
Table 1
Oligonucleotides used in this study
Name Sequence
LytB-N-out 5P-TAGGATCCCCGGCCTACAGATTGCTGCG-3P
LytB-N-in 5P-CCCATCCACTAAACTTAAACACAACAGGATCTGCA-
TGTTACG-3P
LytB-C-in 5P-TGTTTAAGTTTAGTGGATGGGCGTGAAGTCGATT-
AAGTCAT-3P
LytB-C-out 5P-TAGTCGACAGAACCACCCATGATCACC-3P
LytB-con-N 5P-CGATAAAACCACCTTCTCGT-3P
LytB-con-C 5P-ATTGCGGGTAGTTTTCTCAA-3P
Ec-LytB-for 5P-GGATCCATGCAGATCCTGTTGGCCAAC-3P
Ec-LytB-rev 5P-AAGCTTTTAATCGACTTCACGAATATCG-3P
Fig. 2. Gene replacement of lytB with a precisely engineered deletion. A: Diagram of the lytB region of the wild-type strain and the lytB dele-
tion mutant. Small arrows indicate the primer sites used for PCR analysis. The primers were: A, LytB-con-N; B, LytB-con-C. B: Veri¢cation
of the deletion of the lytB gene by PCR. After selection for integrates of the gene replacement vector pKO3-vlytB into the chromosome at
43‡C, bacteria were plated at 30‡C on sucrose medium and replica plated onto chloramphenicol plates. The chloramphenicol-sensitive, sucrose-
resistant colonies were screened by PCR. The PCR product of 560 bp using the primer pair A plus B of the lytB mutant strain is the expected
880 bp smaller than the wild-type product of 1440 bp.
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with the plasmid pQE-lytB. This plasmid was constructed by inserting
the PCR fragment generated using the primers Ec-LytB-for and Ec-
LytB-rev into the BamHI and HindIII sites of the vector pQE30
(Qiagen).
3. Results and discussion
LytB homologs exists in many eubacteria, plants, and in P.
falciparum but are not detectable in animals, archaebacteria or
in S. cerevisiae. The distribution pattern throughout the spe-
cies is identical to Dxr (Table 2). N-terminal sequence exten-
sions of the LytB homologs of the plant Arabidopsis thaliana
and the parasite P. falciparum are likely to represent signal
sequences targeting the polypeptides into the plastids of plants
and the apicoplast (a plastid-like organelle) of malaria para-
sites, respectively (data not shown). Importantly, it needs to
be stressed that the E. coli lytB gene characterized in the
present study [11] is not homologous to the pneumococcal
and streptococcal genes encoding murein hydrolases [16,17]
that incidentally carry the same name.
In order to demonstrate a role for lytB in the MEP path-
way, E. coli cells with a disrupted lytB gene were constructed
and analyzed for loss of their ability to synthesize isoprenoids
by the MEP pathway. Since E. coli mutants blocked in iso-
prenoid biosynthesis are not viable under normal growth con-
ditions [18], E. coli transformants capable of utilizing MVA
for IPP synthesis were used. This strain carries an arti¢cial
operon (pSC-MVA) encoding MVA kinase (Mvk), phospho-
mevalonate kinase (Pmk), and MVA pyrophosphate decar-
boxylase (Mpd) from yeast (Fig. 1) [8]. To inactivate the
lytB gene, its coding sequence was completely removed from
the bacterial genome by homologous recombination and re-
placed by a synthetic 21 bp sequence (Fig. 2A). This was
accomplished by using the pKO3-vlytB gene replacement vec-
tor that allows the generation of a precise in-frame deletion
mutant in E. coli wild-type strain. Bacteria containing the
desired lytB deletion were identi¢ed by PCR analysis (Fig.
2B). Cells deleted for the essential lytB gene were viable
only if the medium was supplemented with MVA or the cells
were complemented with an episomal copy of lytB (Fig. 3).
These data demonstrate that LytB acts in the trunk line of the
MEP pathway upstream of the branching point and most
probably after the formation of 2-C-methyl-D-erythritol 2,4-
cyclodiphosphate (Fig. 1).
Since in the present study LytB could be identi¢ed as an-
other enzyme essential for the MEP pathway that is present in
some important pathogenic agents but absent in mammalians,
it represents an attractive drug target for a new class of anti-
biotics and antimalarials [19^22].
Table 2
Accession numbers of LytB and Dxr homologs in various organ-
isms
Organism LytB Dxr
Eubacteria
Aquifex aeolicus sp O67625 sp P45568
Bacillus subtilis sp P54473 sp O31753
Chlamydia pneumoniae sp Q9Z6P2 sp Q9Z8J8
Chlamydia trachomatis sp O84867 sp O84074
E. coli sp P22565 sp P45568
Haemophilus in£uenzae sp P44976 sp P44055
Helicobacter pylori sp O25160 sp P56139
Mycobacterium tuberculosis sp O53458 sp Q10798
Synechocystis PCC6803 sp Q55643 sp Q55663
Thermotoga maritima sp Q9X1F7 sp Q9WZZ1
Treponema pallidum sp O83558 sp O83610
Neisseria meningitidis tr Q9JR39 sp Q9JX33
Campylobacter jejuni sp P94644 sp Q9PMV3
Deinococcus radiodurans tr Q9RSG0 sp Q9RU84
Pseudomonas aeruginosa tr Q9HVM7 sp Q9KGU6
Vibrio cholerae pir G82293 sp Q9KPV8
Staphylococcus aureus ^ ^
Streptococcus pyogenes ^ ^
Streptococcus pneumoniae ^ ^
Borrelia burgdorferi ^ ^
Mycoplasma genitalium ^ ^
Mycoplasma pneumoniae ^ ^
Rickettsia prowazekii ^ ^
Archaebacteria
Archaeoglobus fulgidus ^ ^
Methanobacterium thermoauto-
trophicum
^ ^
Aeropyrum pernix K1 ^ ^
Methanococcus jannaschii ^ ^
Pyrococcus horikoshii ^ ^
Halobacterium sp. NRC-1 ^ ^
Pyrococcus abyssi ^ ^
Eucaryota
P. falciparum gb AAK12102 tr O96693
A. thaliana pir T04781 sp Q9XFS9
Saccharomyces cerevisiae ^ ^
Drosophila melanogaster ^ ^
Caenorhabditis elegans ^ ^
Homo sapiens ^ ^
^ means not detectable.
Fig. 3. Growth of the E. coli strains indicated in (A) (wtvlytB, lytB deletion mutant; wtvlytB pQE-lytB, lytB deletion mutant complemented
with an episomal copy of the lytB gene) on medium without (B) and with (C) MVA.
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